Congratulations to the team at Alesta Therapeutics on raising an impressive €65 million in their Series A financing! Led by Frazier Life Sciences and Droia Ventures, this round will push their work in rare disease therapies to new levels.
Their lead program, ALE1, targets hypophosphatasia (HPP), a rare genetic disorder, with plans to enter clinical trials in 2025. With a second program addressing Charcot-Marie-Tooth (CMT), Alesta is on a mission to transform patient care in underserved areas.
This milestone shows how innovative science, dedicated leadership, and collaboration with global experts lead to impactful results.
We’re excited to see how this funding accelerates their work to deliver life-changing therapies. And we’re proud to see a company in our community thrive on its journey to make a difference in patients’ lives globally.
Huge congrats to the Alesta team and their partners for this incredible achievement!
Read the full press release here
Professor Meta Roestenberg from Leiden University Medical Center has won the Mercator Sapiens Stimulus prize, worth one million euros, for her work on developing a new malaria vaccine.
450 years of science, innovation, and a thank-you gift that shaped a city—how did Leiden University shape the Bio Science Park we know today? Read on.
The project is focused on improving gene editing and gene therapy manufacturing, strengthening Europe’s position in these areas.